Company intelligence / Profile preview
Neuron23
South San Francisco, California, United Statesneuron23.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Phase 1
01
Overview
Currently conducting a global Phase 2 NEULARK clinical trial of NEU-411 (LRRK2 inhibitor) in early-stage Parkinson's disease, collaborating with Roche to incorporate a digital biomarker as the primary endpoint[5]. Also has Phase 1 programs for NEU-723 (LRRK2 inhibitor) and NEU-111 (TYK2 inhibitor)[6].
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
RocheOrigenis GmbH
Beyond the preview
Go deeper on Neuron23.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuron23.